AC Immune SA

NasdaqGM:ACIU Lagerbericht

Marktkapitalisierung: US$374.9m

AC Immune Management

Management Kriterienprüfungen 3/4

AC Immune's CEO ist Andrea Pfeifer , ernannt in Apr 2003, hat eine Amtszeit von 21.17 Jahren. Die jährliche Gesamtvergütung beträgt CHF2.65M , bestehend aus 21.8% Gehalt und 78.2% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 2.58% der Aktien des Unternehmens, im Wert von $9.88M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.8 Jahre bzw. 6.2 Jahre.

Wichtige Informationen

Andrea Pfeifer

Geschäftsführender

CHF 2.7m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts21.8%
Amtszeit als Geschäftsführer21.2yrs
Eigentum des Geschäftsführers2.6%
Durchschnittliche Amtszeit des Managements3.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder6.2yrs

Jüngste Management Updates

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Jun 15
Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Recent updates

AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Jun 15
AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Jun 15
Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

May 24
AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Apr 05
AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Mar 15
We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth

Oct 06
Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Jun 03
We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

Nov 25
Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

AC Immune Non-GAAP EPS of -$0.23 in-line

Jul 28

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

Jul 06
Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Feb 03
AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates

Jun 02

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

May 09
Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

AC Immune reports Q1 results; outlook

Apr 28

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Feb 28
How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

Jan 24
Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

Jan 19
We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Dec 15
If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

Nov 19
Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

AC Immune EPS misses by CHF0.02, beats on revenue

Nov 13

AC Immune and Wuxi Biologics boost development of TDP-43 antibodies

Nov 09

AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 30

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Andrea Pfeifer im Vergleich zu den Einnahmen von AC Immune verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2024n/an/a

-CHF 55m

Dec 31 2023CHF 3mCHF 578k

-CHF 54m

Sep 30 2023n/an/a

-CHF 68m

Jun 30 2023n/an/a

-CHF 67m

Mar 31 2023n/an/a

-CHF 69m

Dec 31 2022CHF 2mCHF 558k

-CHF 71m

Sep 30 2022n/an/a

-CHF 73m

Jun 30 2022n/an/a

-CHF 76m

Mar 31 2022n/an/a

-CHF 75m

Dec 31 2021CHF 2mCHF 530k

-CHF 73m

Sep 30 2021n/an/a

-CHF 71m

Jun 30 2021n/an/a

-CHF 74m

Mar 31 2021n/an/a

-CHF 71m

Dec 31 2020CHF 2mCHF 520k

-CHF 62m

Sep 30 2020n/an/a

-CHF 62m

Jun 30 2020n/an/a

-CHF 25m

Mar 31 2020n/an/a

-CHF 26m

Dec 31 2019CHF 2mCHF 510k

CHF 45m

Sep 30 2019n/an/a

CHF 50m

Jun 30 2019n/an/a

CHF 18m

Mar 31 2019n/an/a

CHF 24m

Dec 31 2018CHF 2mCHF 455k

-CHF 51m

Sep 30 2018n/an/a

-CHF 32m

Jun 30 2018n/an/a

-CHF 27m

Mar 31 2018n/an/a

-CHF 29m

Dec 31 2017CHF 2mCHF 404k

-CHF 26m

Vergütung im Vergleich zum Markt: AndreaDie Gesamtvergütung ($USD3.00M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD2.44M).

Entschädigung vs. Einkommen: AndreaDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Andrea Pfeifer (67 yo)

21.2yrs

Amtszeit

CHF 2,650,000

Vergütung

Prof. Dr. Andrea Pfeifer, Ph.D. has been the Chief Executive Officer of AC Immune SA since 2003. Prof. Dr. Pfeifer Co-founded AC Immune SA in April 2003. She serves as an Advisor and Chairwoman of BioMedPa...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Andrea Pfeifer
Co-Founder21.2yrsCHF 2.65m2.58%
CHF 9.7m
Christopher Roberts
CFO & VP of Finance2.2yrskeine Daten0.013%
CHF 50.3k
Piergiorgio Donati
Chief Technical Operations Officer5.3yrskeine Daten0.026%
CHF 97.8k
Jean-Fabien Monin
Chief Administrative Officer8.9yrskeine Daten0.33%
CHF 1.2m
Howard Donovan
Chief HR Officer2.2yrskeine Daten0.021%
CHF 80.3k
Nuno Mendonca
Chief Medical Officerless than a yearkeine Daten0.0088%
CHF 32.8k
Madiha Derouazi
Chief Scientific Officerless than a yearkeine Daten0.0034%
CHF 12.7k
Gary Waanders
Senior VP of Investor Relations & Corporate Communicationsno datakeine Datenkeine Daten
Alexandre Caratsch
General Counselno datakeine Datenkeine Daten
Julian Snow
VP of U.S. Finance & Corporate Development2.2yrskeine Datenkeine Daten
David Hickman
Head of AD - SME14.4yrskeine Datenkeine Daten
Joseph Wettstein
Head of Non-AD Proteinopathies & Deputy Chief Scientific Officer8.3yrskeine Datenkeine Daten

3.8yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrenes Management: ACIUDas Führungsteam des Unternehmens gilt als erfahren (3.8 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Andrea Pfeifer
Co-Founder8.1yrsCHF 2.65m2.58%
CHF 9.7m
Jean-Marie Lehn
Chairman of Scientific Advisory Boardno datakeine Datenkeine Daten
Claude Nicolau
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Douglas Williams
Independent Non-Executive Chairman6.2yrsCHF 179.00k0.041%
CHF 155.3k
Alf E. Lindberg
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Detlev Riesner
Member of Scientific Advisory Boardno dataCHF 5.00kkeine Daten
Fred Van Leuven
Member of Scientific Advisory Boardno dataCHF 105.00kkeine Daten
I. Rosenberg
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
M. Monsigny
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
E. Lestringant
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Monika Butler
Independent Vice Chair2.7yrsCHF 163.00k0.0097%
CHF 36.5k
Andreas Monsch
Head of Clinical Advisory Boardno datakeine Datenkeine Daten

6.2yrs

Durchschnittliche Betriebszugehörigkeit

74.5yo

Durchschnittliches Alter

Erfahrener Vorstand: ACIUDie Vorstandsmitglieder gelten als erfahren (6.2 Jahre durchschnittliche Amtszeit).